On Thursday, the Supreme Court handed the Trump administration another significant victory in its attempts to defund NIH-sponsored research. In a 5-4 decision, the justices paused the June 16 order of U.S. District Judge William Young to restore funding for hundreds of canceled NIH research grants focusing on gender and diversity, equity and inclusion (DEI). The funding had first been cut through a series of executive orders shortly after President Donald Trump resumed power in January.

Jocasta Neuroscience Inc. has raised $35 million in a series A financing to advance its lead asset, JN-0413, a proprietary formulation of the longevity protein α-Klotho, through phase I development. The company is targeting an IND submission for the fourth quarter of next year.

Mabylon AG has raised a total of CHF30 million (US$37 million) to advance its pipeline and support its work using human-derived, multi-specific antibodies for the treatment of allergies. The funding combines equity investment and a convertible loan.

Equillium Inc. has entered into a definitive securities purchase agreement with health care investors that will provide up to $50 million in gross proceeds to Equillium. The private placement will enable the company to advance its selective aryl hydrocarbon receptor (AhR) modulator EQ-504 into the clinic.

Lysoway Therapeutics Inc. announced that it has received a research grant of $2.93 million from The Michael J. Fox Foundation for Parkinson's Research. The funding will support the preclinical development of Lysoway’s highly brain-penetrant small molecule mucolipin TRP Cation channel 1 (MCOLN1/TRPML1) agonist.

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With offices in Philadelphia and San Francisco, Dispatch has raised $216 million since its founding in 2022. The firm’s platform delivers a cell-specific viral vector carrying a novel, universal antigen called Flare that tags solid, epithelial-derived tumor cells. Acting as a beacon, the Flare antigen directs the immune system to find and clear the cancer cells without harming healthy tissue.

Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s neuroimmunology portfolio.

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development of an insulin and glucagon combination product that the company has been in the process of developing for approximately 18 months. “We’re very excited that this round is able to get us positioned for a successful series A once we meet some internal confidential milestones,” Edward Raskin, CEO of Abvance, told BioWorld.

Newco Elkedonia SAS has raised €11 million (US$12.7 million) in a seed round, which will fund it to take a potentially first-in-class ELK-1 inhibitor into the clinic in the treatment of refractory depression. ELK-1 plays a pivotal role in neuroplasticity and in reward circuits in the brain, which when disrupted can lead to depression, addiction and post-traumatic stress disorder.